Precision Prevention Research Program
Description: PROJECT NARRATIVE Although substantial evidence demonstrating that low-dose aspirin (LDA) reduces risk of colorectal cancer (CRC) and likely other cancers has led to formal recommendations for LDA to prevent CRC, there remains a high unmet need to provide to develop precision biomarkers to optimize targeting populations for treatment with a favorable risk-benefit ratio. In this Outstanding Investigator Award, I propose a Precision Prevention Research Program to enhance molecularly characterized prospective cohort studies to test hypotheses that can then be tested for causality through cost-efficient, biomarker-driven clinical cohorts in which human tissues can be leveraged to develop “living biobanks” for rapid translational testing. These complementary approaches will empower my research team to study the entire continuum from healthy individuals to advanced cancer patients and from single cells to large populations to obtain a more complete, multifaceted view of how interventions can be tailored to prevent cancer.
Funder: National Cancer Institute
Funding type: research
Funder scheme: R35
Start date: 2020-09-01
End date: 2027-08-31
Investigator: ANDREW T CHAN (lead)
Institution: Massachusetts General Hospital
Subfield: Pharmacology (medical)
Field: Medicine
Domain: Health Sciences
Funded outputs count: 140
Funder award ID: R35CA253185
OpenAlex ID: G9000883203